World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
131
Citations
95110
World Ranking
2344
National Ranking
53

Giovanni Scambia publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giovanni Scambia sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 2,292 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giovanni Scambia D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giovanni Scambia sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 131 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Giovanni Scambia is affiliated with the Catholic University of the Sacred Heart in Italy. Their research contributions mainly focus on medicine, with a total of 1801 publications. Within this broad field, their work is concentrated in several subfields including obstetrics and gynecology, reproductive medicine, surgery, oncology, and epidemiology.

The scientist has extensively investigated topics related to cancer and reproductive health. Key areas of research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, PARP inhibition in cancer therapy, uterine myomas and treatments, endometriosis research and treatment, cervical cancer and HPV research, and intraperitoneal and appendiceal malignancies.

Frequently publishing in leading journals, Giovanni Scambia's most productive publication venues include:

  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Cancers
  • European Journal of Surgical Oncology
  • Facts Views and Vision in ObGyn

Collaboration has played a significant role in their research, with frequent co-authors including:

  • Anna Fagotti
  • Francesco Fanfani
  • Domenica Lorusso
  • Giuseppe Vizzielli
  • Gabriella Ferrandina

The scientist has contributed to numerous peer-reviewed articles. Selected recent papers are:

  • "Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis," 2020, American Journal of Obstetrics & Gynecology MFM
  • "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial," 2022, Journal of Clinical Oncology
  • "Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)," 2020, International Journal of Gynecological Cancer
  • "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study," 2021, The Lancet Oncology

Best Publications

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    Pierluigi Benedetti Panici;Stefano Basile;Francesco Maneschi;Andrea Alberto Lissoni

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.

    Daniele Di Mascio;Asma Khalil;Gabriele Saccone;Giuseppe Rizzo

  • Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

    A. Bellacosa;D. De Feo;A. K. Godwin;D. W. Bell

  • Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

    Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso

  • Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

    Pierluigi Benedetti Panici;Angelo Maggioni;Neville Hacker;Fabio Landoni

  • Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies

    Thomas Hogberg;Mauro Signorelli;Carlos Freire de Oliveira;Roldano Fossati

  • Local-Regional Staging of Endometrial Carcinoma: Role of MR Imaging in Surgical Planning

    Riccardo Manfredi;Paoletta Mirk;Giulia Maresca;Pasquale A. Margariti

  • A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Philipp Harter;Jalid Sehouli;Domenica Lorusso;Alexander Reuss

  • CLASS III BETA-TUBULIN OVEREXPRESSION IS A PROMINENT MECHANISM OF PACLITAXEL RESISTANCE IN OVARIAN CANCER PATIENTS

    Simona Mozzetti;Cristiano Ferlini;Paola Concolino;Flavia Filippetti

  • Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample.

    Maria Marone;Simona Mozzetti;Daniela De Ritis;Luca Pierelli

  • Role of microRNAs in drug-resistant ovarian cancer cells

    Antonio Sorrentino;Antonio Sorrentino;Chang Gong Liu;Antonio Addario;Cesare Peschle

  • A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.

    Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Alfredo Ercoli

  • Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

    Anna Fagotti;Gabriella Ferrandina;Giuseppe Vizzielli;Francesco Fanfani

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

    G. Scambia;F. O. Ranelletti;P. Benedetti Panici;R. De Vincenzo

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

Frequent Co-Authors

Gabriella Ferrandina
Gabriella Ferrandina Catholic University of the Sacred Heart
Salvatore Mancuso
Salvatore Mancuso Catholic University of the Sacred Heart
Domenica Lorusso
Domenica Lorusso Catholic University of the Sacred Heart
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Sandro Pignata
Sandro Pignata National Cancer Institute
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Fabio Ghezzi
Fabio Ghezzi University of Insubria
Francesco Cosentino
Francesco Cosentino Karolinska University Hospital
Pierluigi Benedetti Panici
Pierluigi Benedetti Panici Sapienza University of Rome
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a variety of online healthcare degrees and specialized career pathways. For students who prefer flexible learning or require cost-efficient options, online programs have become more accessible and diverse.

One fast-growing field is medical administration. Taking medical billing and coding cost into consideration, online courses can be a practical entry point into healthcare with manageable fees and job-ready skills.

Aspiring nurses can discover several affordable nursing programs online, making it easier to earn a degree without a heavy financial burden. Those looking to advance in their careers may consider the cheapest nurse practitioner programs, combining affordability with qualification development.

For those aiming for academic or leadership roles in healthcare, pursuing an online phd nursing can offer flexibility and cost savings. These pathways not only expand career options but also help meet the growing demand for healthcare professionals in the USA.

Best Scientists Citing Giovanni Scambia

Trending Scientists

Recently Published Articles